logo
Bad News for Movie Studios: Authors Just Lost on a Key Issue In a Major AI Lawsuit

Bad News for Movie Studios: Authors Just Lost on a Key Issue In a Major AI Lawsuit

Yahoo6 hours ago

Transformative.
That's how a federal court characterized Amazon-backed Anthropic's use of millions of books across the web to teach its artificial intelligence system. It's the first decision to consider the issue and will serve as a template for other courts overseeing similar cases. And studios, now that some have entered the fight over the industry-defining technology, should be uneasy about the ruling.
More from The Hollywood Reporter
Netflix Founder Reed Hastings Joins Board of AI Giant Anthropic
Anthropic Wins First Round In Lawsuit From Music Publishers Over Song Lyrics
Music Publishers Reach Deal With AI Giant Anthropic Over Copyrighted Song Lyrics
The thrust of these cases will be decided by one question: Are AI companies covered by fair use, the legal doctrine in intellectual property law that allows creators to build upon copyrighted works without a license? On that issue, a court found that Anthropic is on solid legal ground, at least with respect to training.
The technology is 'among the most transformative many of us will see in our lifetimes,' wrote U.S. District Judge William Alsup.
Still, Anthropic will face a trial over illegally downloading seven millions books to create a library that was used for training. That it later purchased copies of those books it stole off the internet earlier to cover its tracks doesn't absolve it of liability, the court concluded. The company faces potential damages of hundreds of millions of dollars stemming from the decision that could lead to Disney and Universal getting a similar payout depending on what they unearth in discovery over how Midjourney allegedly obtained copies of thousands of films that were repurposed to teach its image generator.
Last year, authors filed a lawsuit against Anthropic accusing it of illegally downloading and copying their books to power its AI chatbot Claude. The company chose not to move to dismiss the complaint and instead skipped straight for a decision on fair use.
In the ruling, the court found that authors don't have the right to exclude Anthropic from using their works to train its technology, much in the same way they don't have the right to exclude any person from reading their books to learn how to write.
'Everyone reads texts, too, then writes new texts,' reads the order. 'They may need to pay for getting their hands on a text in the first instance. But to make anyone pay specifically for the use of a book each time they read it, each time they recall it from memory, each time they later draw upon it when writing new things in new ways would be unthinkable.'
If someone were to read all the modern-day classics, memorize them and emulate a blend of their writing, that wouldn't constitute copyright infringement, the court concluded. Like any reader who wants to be a writer, Anthropic's technology draws upon works not to replicate or supplant them but to create something entirely different, according to the order.
Those aren't the findings that Disney or Universal — both of whom are suing Midjourney for copyright infringement — wanted or expected. For them, there's reason to worry that Alsup's analysis will shape the way in which the judge overseeing their case considers undermining development of a technology that was found by another court to be revolutionary (or something close to it). More broadly, it could be found that AI video generators, like Sora, are simply distilling every movie ever made to create completely new works.
'This Anthropic decision will likely be cited by all creators of AI models to support the argument that fair use applies to the use of massive datasets to train foundational models,' says Daniel Barsky, an intellectual property lawyer at Holland & Knight.
Important to note: The authors didn't allege that responses generated by Anthropic infringed upon their works. And if they had, they would've lost that argument under the court's finding that guardrails are in place to ensure that no infringing ever reached users. Alsup compared it to Google imposing limits on how many snippets of text from any one book could be seen by a user through its Google Book service, preventing its search function from being misused as a way to access full books for free.
'Here, if the outputs seen by users had been infringing, Authors would have a different case,' Alsup writes. 'And, if the outputs were ever to become infringing, Authors could bring such a case. But that is not this case.'
But that could be the case for Midjourney, which returns nearly exact replicas of frames from films in some instances.
When prompted with 'Thanos Infinity War,' Midjourney — an AI program that translates text into hyper-realistic graphics — replied with an image of the purple-skinned villain in a frame that appears to be taken from the Marvel movie or promotional materials, with few to no alterations made. A shot of Tom Cruise in the cockpit of a fighter jet, from Top Gun: Maverick, is produced when the tool was asked for a frame from the film. The chatbots can seemingly replicate almost any animation style, generating startlingly accurate characters from titles ranging from DreamWorks' Shrek to Pixar's Ratatouille to Warner Bros.' The Lego Movie.
'The fact that Midjourney generates copies and derivatives of' films from Disney and Universal proves that the company, without their knowledge or permission, 'copied plaintiffs' copyrighted works to train and develop' its technology, states the complaint.
Also at play: The possibility that Midjourney pirated the studios' movies. In the June 23 ruling, Alsup found that Anthropic illegally downloading seven million books to build a library to be used for training isn't covered by fair use. He said that the company could've instead paid for the copies. Such piracy, the court concluded, is 'inherently, irredeemably infringing.'
With statutory damages for willful copyright infringement reaching up to $150,000 per work, massive payouts are a possibility.
Best of The Hollywood Reporter
How the Warner Brothers Got Their Film Business Started
Meet the World Builders: Hollywood's Top Physical Production Executives of 2023
Men in Blazers, Hollywood's Favorite Soccer Podcast, Aims for a Global Empire

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Angelina Jolie Has Some Thoughts on Brad Pitt's AA Meeting Reveal, Says ‘Source'
Angelina Jolie Has Some Thoughts on Brad Pitt's AA Meeting Reveal, Says ‘Source'

Yahoo

time32 minutes ago

  • Yahoo

Angelina Jolie Has Some Thoughts on Brad Pitt's AA Meeting Reveal, Says ‘Source'

recently shared his experience about his AA meetings post-divorce with Angelina Jolie. The 'F1' star appeared on the latest episode of the 'Armchair Expert' podcast, where he told Dax Shepard about his time with Alcoholics Anonymous. However, a source claimed that his ex-wife allegedly has some thoughts about the interview. Reportedly, Pitt's confession felt like a 'PR' to her. Brad Pitt opened up about his 'difficult time' when he hit rock bottom after his separation from Angelina Jolie. In an interview with Dax Shepard on the 'Armchair Expert' podcast, he revealed that he was on his 'knees' during his journey to become sober. Further, he shared his experience during his AA (Alcoholics Anonymous) meetings. While fans sympathized with Pitt's confession, his ex-wife might not think the same. According to ShuterScoop, a source said, 'To her, it feels like PR — not personal growth.' It seemed she was not buying her ex-husband's story and 'doesn't think a podcast fixes everything.' 'Brad's version plays well to the public, but behind the scenes, it's still a mess,' the insider added. In the podcast interview, the 'Fight Club' star stated that he was trying everything his well-wishers recommended. He confessed that he 'needed rebooting.' 'I needed to wake the f—— up in some areas. And it just meant a lot to me,' Pitt told Shepard. The 'Mr. & Mrs. Smith' co-stars tied the knot in 2016. After two years, Jolie filed for divorce, which was finalized in December 2024. They went through an eight-year-long legal battle, fighting over their custody of six kids — Maddox, Pax, Zahara, Shiloh, and twins Vivienne and Knox. Later, the mother won custody, followed by a rocky relationship between Pitt and the children. Over time, several sources claimed that the 61-year-old actor blamed Jolie for their kids' behaviour. Meanwhile, Pitt is currently dating jewelry designer Ines de Ramon. Originally reported by Sushmita Sen on Reality Tea. The post Angelina Jolie Has Some Thoughts on Brad Pitt's AA Meeting Reveal, Says 'Source' appeared first on Mandatory.

Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation
Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation

Yahoo

time36 minutes ago

  • Yahoo

Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation

Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation Ongoing phase 2 study evaluating riliprubart for the potential prevention and treatment of active antibody-mediated rejection in kidney transplant recipients Riliprubart was also designated orphan drug for the investigational use in chronic inflammatory demyelinating polyneuropathy in the US and EU Paris, June 25, 2025. The US Food and Drug Administration (FDA) has granted orphan drug designation to riliprubart for the investigational treatment of antibody-mediated rejection (AMR) in solid organ transplantation. This designation reflects Sanofi's commitment to addressing a critical unmet need in transplant medicine, where AMR remains a significant challenge with no FDA-approved treatments available. The FDA grants orphan drug designation to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people in the US. Global Therapeutic Area Development Head, Immunology and Inflammation, Sanofi"Orphan drug designation for riliprubart marks an important milestone in our mission to address critical challenges in transplant medicine leveraging our expertise in immunology. Antibody mediated rejection represents a serious threat to transplanted organs and patient survival. Through riliprubart's innovative mechanism of action, we hope to bring forward a treatment option that could significantly improve outcomes for kidney transplant recipients." Riliprubart is currently being explored in multiple clinical studies across different indications in transplant and neurology. A phase 2 clinical study is currently ongoing, exploring its potential in kidney transplant recipients (NCT05156710). The study includes two patient cohorts: those at risk of developing rejection and those with active forms of antibody-mediated rejection. In addition, Sanofi is conducting two phase 3 studies exploring riliprubart in chronic inflammatory demyelinating polyneuropathy (CIPD), a rare neurological disorder, specifically in patients refractory to standard of care (MOBILIZE, clinical study identifier: NCT06290128), and in IVIg-treated patients (VITALIZE, clinical study identifier: NCT06290141). The broad clinical development program for riliprubart emphasizes Sanofi's commitment to exploring riliprubart's potential across multiple immune-mediated conditions with high unmet medical needs. About Riliprubart SAR445088 (riliprubart) is a potential first-in-class, IgG4 humanized monoclonal antibody that selectively inhibits activated C1s in the classical complement pathway of the innate immune system. Riliprubart is currently under clinical investigation, and its safety and efficacy have not been evaluated by any regulatory authority. For more information on riliprubart clinical studies, please visit About AMRAntibody-mediated rejection is a serious complication that may arise after solid organ transplantation, occurring when the recipient's immune system produces antibodies that attack the transplanted organ. Sensitized recipients, who have pre-existing antibodies that target foreign antigens including those found on transplanted organs, face a high risk of developing antibody-mediated rejection. Subsequent immune response can lead to inflammation, organ damage, and organ failure if left untreated. About Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY Media RelationsSandrine Guendoul | +33 6 25 09 14 25 | Evan Berland | +1 215 432 0234 | Léo Le Bourhis | +33 6 75 06 43 81 | Victor Rouault | +33 6 70 93 71 40 | Timothy Gilbert | +1 516 521 2929 | Léa Ubaldi | +33 6 30 19 66 46 | Investor RelationsThomas Kudsk Larsen | +44 7545 513 693 | Alizé Kaisserian | +33 6 47 04 12 11 | Felix Lauscher | +1 908 612 7239 | Keita Browne | +1 781 249 1766 | Nathalie Pham | +33 7 85 93 30 17 | Tarik Elgoutni | +1 617 710 3587 | Thibaud Châtelet | +33 6 80 80 89 90 | Yun Li | +33 6 84 00 90 72 | Sanofi forward-looking statementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words 'expects', 'anticipates', 'believes', 'intends', 'estimates', 'plans' and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under 'Risk Factors' and 'Cautionary Statement Regarding Forward-Looking Statements' in Sanofi's annual report on Form 20-F for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. All trademarks mentioned in this press release are the property of the Sanofi group. Attachment Press Release

Truist Lowers GitLab (GTLB) PT to $75, Maintains Buy Rating
Truist Lowers GitLab (GTLB) PT to $75, Maintains Buy Rating

Yahoo

time36 minutes ago

  • Yahoo

Truist Lowers GitLab (GTLB) PT to $75, Maintains Buy Rating

GitLab Inc. (NASDAQ:) is one of the best technology stocks according to Wall Street analysts. Earlier on June 12, Truist adjusted the price target for GitLab to $75 from $80, while maintaining a Buy rating on the shares. This revision comes after GitLab's Q1 2025 results, which, although exceeding guidance, did not meet investor expectations for a larger beat. In Q1, the company reported a total revenue of $169.2 million, which marked a 33% increase year-over-year. GitLab also generated positive cash flow for the first time in a first quarter. The subscription revenue from self-managed and SaaS grew to $151.179 million from $111.191 million year-over-year, and license revenue from self-managed and other increased to $18.008 million from $15.687 million. A team of software engineers working together in an open office, developing innovative solutions. The company's customer base also expanded, with customers contributing over $5,000 of ARR, reaching 8,976, which showed a 21% increase year-over-year. Customers with over $100,000 of ARR grew by 35% year-over-year, totaling 1,025. In this quarter, GitLab also received the 2024 Google Cloud Technology Partner of the Year Award in the Application Development – DevOps category. GitLab Inc. (NASDAQ:GTLB) develops software for the software development lifecycle in the US, Europe, and the Asia Pacific. While we acknowledge the potential of GTLB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store